This process applies whether you are using 1.0 mL, 2.0 mL, or any other volume from the chart above
Lilly's TRIUMPH clinical program includes multiple Phase III trials evaluating retatrutide across different patient populations and endpoints: Seven additional Phase III readouts are expected throughout 2026, covering populations with type 2 diabetes, cardiovascular disease, obstructive sleep apnea, and other obesity-related comorbidities Cardiovascular outcomes data the gold standard for demonstrating that weight loss translates into reduced heart attacks, strokes, and cardiovascular death will be critical for retatrutide's regulatory and commercial positioning Head-to-head trials comparing retatrutide directly to existing therapies may provide definitive comparative efficacy data The Drug vs
Mistake 6: Stopping fiber during side effect flares When GLP-1 side effects intensify, especially after dose increases, many users stop all supplements including fiber
Ask a doctor or pharmacist if you take other medications
The most common side effects are GI-related, many of which improve as you continue treatment